Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Most prostate cancers eventually become castration resistant and stop responding to hormone therapy. In other words, they continue to grow even in the presence of extremely low or undetectable levels of androgen in the body. Every year, more than 1.4 million men are affected by prostate cancer worldwide, placing a significant burden on patients and healthcare systems. Although prostate cancer is frequently found in its early, localized stages, 20% of men with localized disease go on to develop metastatic, hormone-sensitive prostate cancer (mHSPC) five years after receiving their initial diagnosis. Treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have significantly evolved in recent years. Androgen deprivation therapy (ADT) was the sole treatment option for mHSPC for a long time.

Description

Over time, the majority of prostate cancers become castration resistant and stop responding to hormone therapy. In other words, they continue to grow even in the presence of extremely low or undetectable levels of androgen in the body. Because the tumors do not actually depend on androgens for growth, the terms hormone resistant, androgen independent, or hormone refractory are no longer frequently used to describe them. A common strategy is androgen deprivation therapy (ADT), which has been the cornerstone of treatment for locally advanced and metastatic prostate cancer for the past 70 years. ADT will typically produce a biochemical and clinical response in the majority of patients, but all will eventually develop castrate resistance. Treatment options for men with castrate-resistant prostate cancer (CRPC) and overall survival rates have significantly increased since 2004. The management of metastatic castrate-sensitive or hormone-naive disease, also known as metastatic hormone-sensitive prostate cancer (mHSPC), has made little progress up until very recently.

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (Epidemiology)

More than 1.4 million men worldwide are diagnosed with prostate cancer every year, placing a significant burden on patients and healthcare systems. Even though localized prostate cancer is frequently diagnosed in its early stages, 20% of men with localized disease go on to develop metastatic, hormone-sensitive prostate cancer (mHSPC) within five years of their initial diagnosis. Six to eight% of all prostate cancer patients in the US and Germany receive a direct diagnosis at the metastatic stage (de novo mHSPC). Androgen deprivation therapy (ADT) is crucial in the treatment of people with mHSPC. ADT in conjunction with docetaxel, as well as more recent androgen receptor axis-targeted therapies (ARATs) like abiraterone acetate, enzalutamide, and apalutamide, as well as radiotherapy to the prostate, have all been shown to significantly improve disease progression and survival in patients with metastatic high-risk prostate cancer (mHSPC).

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) -Current Market Size & Forecast Trends

The market for metastatic hormone-sensitive prostate cancer (mHSPC) is expected to grow significantly, with projections indicating an increase from approximately USD 5.5 billion in 2024 to around USD 9.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of about 5.3% during this period. This growth is driven by the rising incidence of prostate cancer, particularly among aging populations, and advancements in treatment options, including next-generation hormonal therapies such as abiraterone acetate and enzalutamide, which have shown effectiveness in managing mHSPC. The increasing focus on early diagnosis and personalized treatment approaches is also contributing to market expansion. Additionally, the integration of innovative therapies and ongoing clinical trials aimed at improving patient outcomes are expected to further enhance the market landscape through 2035. Overall, the mHSPC market is well-positioned for substantial growth as new treatment strategies emerge and awareness of the disease increases.

The range of treatments available for metastatic hormone-sensitive prostate cancer (mHSPC) has significantly expanded recently. Androgen deprivation therapy (ADT) was the sole method of treatment for mHSPC for a long time. This changed after it was discovered that patients with mHSPC have a significantly higher overall survival rate when docetaxel chemotherapy or abiraterone acetate are combined with ADT. This was followed by more recent research showing how androgen receptor antagonists like enzalutamide and apalutamide work in this circumstance. Androgen axis inhibitors are being tested in numerous ongoing registration trials in men with mHSPC, either alone or in combination with docetaxel. Even though these regimens are more effective than standard ADT, not all men with mHSPC are candidates for intensified upfront treatment. This is due to the fact that they cost more and have more side effects. Additionally, data from the SWOG9346 trial suggests that there is a subset of men with mHSPC who have excellent overall survival (OS) with standard continuous ADT (7 years) and may not require such aggressive upfront treatment.

Report Highlights

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) - Current Market Trends

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) - Current & Forecasted Cases across the G8 Countries

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) - Market Opportunities and Sales Potential for Agents

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) - Patient-based Market Forecast to 2035

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) - Untapped Business Opportunities

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) - Product Positioning Vis-a-vis Competitors' Products

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) - KOLs Insight